Displaying drugs 14576 - 14600 of 14838 in total
Plinabulin
Investigational
Lauroyl chloride
Experimental
Betaine aldehyde
Experimental
2,3-Dimethyl-1,4-naphthoquinone
Experimental
Acetyl chloride
Experimental
VLTS-589
VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational
BTA9881
BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational
CHGN111
CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. It...
Investigational
3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol
Experimental
1-Amino-1-Carbonyl Pentane
Experimental
Acetophenone
Experimental
P-Hydroxybenzaldehyde
Experimental
R1295
R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Investigational
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Mebicar
Experimental
Lawsone
Experimental
Displaying drugs 14576 - 14600 of 14838 in total